BGB 23339
Alternative Names: BGB-23339Latest Information Update: 27 Dec 2022
At a glance
- Originator BeiGene
- Class Anti-inflammatories
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammation
Most Recent Events
- 17 Oct 2022 BeiGene withdraws a phase I clinical trial in healthy volunteers prior to enrolment, as sponsor determined the data was no longer needed (PO, Tablet) (NCT05387668)
- 15 Sep 2022 BeiGene completes a phase I trial in Inflammation (Monotherapy; In volunteers) in Australia and China (NCT05093270)
- 26 May 2022 BeiGene plans a phase I pharmacokinetics trial in Japanese and Caucasian (In adults, In volunteers) in June 2022 (PO) (NCT05387668)